InsidersTradesSigma
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Browse the detailed record of transactions filed by Kelly Paul Edward, 董事. Director active across 1 company, notably Relmada Therapeutics, INC.. Cumulatively, 5 disclosures have been published. Breakdown: 3 buys · 0 sell. Total volume traded: €308k. Activity tracked since 3 January 2022. The latest transaction was filed on 5 November 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 条申报中的 5 条
Paul Edward Kelly is a Board Member of Relmada Therapeutics, Inc., a biotechnology company. As a board member, he participates in overseeing the company's activities and making strategic decisions. His expertise in the biotechnology field is valuable for guiding Relmada's initiatives.